Alchemia begins patient enrolment for Phase II trial of HA-Irinotecan and Erbitux

Australia-based Alchemia has started patient enrolment of the new clinical trial of HA-Irinotecan and Erbitux (cetuximab) called the CHIME trial.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news